Britain’s regulator approves a dose of up to 7.2 mg of semaglutide per week, up from 2.4 mg.

The past couple of years have been challenging for the company. But this could be the beginning of a new chapter.

Novo Nordisk entered 2026 with fresh momentum after the U.S. launch of its oral Wegovy pill. Is the stock a buy now?

By Bhanvi Satija and Maggie Fick LONDON, Jan 16 (Reuters) - Novo Nordisk's Wegovy weight-loss pill has made an encouraging ...

Jan 9 (Reuters) - Amazon Pharmacy said on Friday it now offers Novo Nordisk's Wegovy weight-loss pill through insurance plans ...

TUESDAY, Jan. 6, 2026 (HealthDay News) — A daily pill for weight loss has officially arrived in the U.S. On Monday, Novo Nordisk rolled out the first GLP-1 weight-loss pill, an oral version of Wegovy.

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...

Novo Nordisk announced Jan. 5 it will begin offering its Wegovy weight loss pill to self-paying patients in the United States, expanding access to the popular GLP-1 medication beyond injections.

Two weeks after securing approval from the U.S. Food and Drug Administration, a once-daily pill version of Novo Nordisk‘s popular GLP-1 weight loss drug Wegovy officially hit the market. In a Jan. 5 ...

Novo Nordisk executive Dave Moore touted high interest in Wegovy's oral version of its injectable GLP-1 weight-loss ...

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy.